CorMedix Q1 prelim revenue $39.0M, raises H1 2025 net sales guidance to $62-$70M

CorMedix Inc.

2025-Q1 EPS reported $0.30 revenue$39,081,657

Preliminary unaudited Q1 2025 net revenue of $39.0M; expects adjusted EBITDA above $22.5M.
Raises H1 2025 net sales guidance for existing purchasing customers to $62M-$70M from prior range.
Cash and short-term investments at March 31, 2025: approx. $77.5M.
Phase 3 TPN study of DefenCath enrollment expected to begin late April; peak sales potential $150M-$200M.
Forecasts patient utilization growth in H2 2025; unit shipments expected to exceed H1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.